Customize this page|
0
Votes
vote
Study: HBV genotype is not linked to hepatocellular carcinomaPrevious studies revealed that HBV genotypes as well as mutations in the core promoter, precore or HBx gene have been shown to have an association with the clinical outcome of liver disease, however, this is still controversial. It is likely that this depends on the HBV genotype distribution in c... |
|
0
Votes
vote
Trabedersen granted orphan drug designation from both FDA And EMEA for treating pancreatic carcinomaThe biopharmaceutical company Antisense Pharma GmbH has announced today that it has received orphan drug designation from both the European Medicines Agency EMEA and the US Food and Drug Administration FDA for its investigational drug trabedersen in the treatment of pancreatic carcinoma. ... |
|
2
Votes
vote
Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumorsEndo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for the treatment of a distinct form of bladder cancer. VALSTAR is the only FDA-approved intravesical therapy for patients with Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the ... |
